Literature DB >> 11596735

Hematologic abnormalities and outcome of 16 cats with myelodysplastic syndromes.

M Hisasue1, H Okayama, T Okayama, T Suzuki, T Mizuno, Y Fujino, K Naganobu, A Hasegawa, T Watari, N Matsuki, K Masuda, K Ohno, H Tsujimoto.   

Abstract

We investigated the hematologic abnormalities and prognoses in 16 cats with myelodysplastic syndromes (MDS). Nonregenerative anemia, thrombocytopenia, and neutropenia were observed in 15, 13, and 4, respectively, of the 16 cats with MDS. Morphologic abnormalities characteristic of MDS included megaloblastoid rubricytes (9 cats), hyposegmentation of neutrophils (7 cats), nuclear abnormality of rubricytes (10 cats) and neutrophils (13 cats), and micromegakaryocytes (10 cats). Disease in these 16 cats was subclassified into refractory anemia (RA; 8 cats), RA with excess of blasts (RAEB; 5 cats), RAEB in transformation (RAEB in T; 1 cat), and chronic myelomonocytic leukemia (CMMoL; 2 cats), according to the human French-American-British (FAB) classification. In the cats in which the clinical outcome was known, 3 of 6 cats with high blast cell count MDS, including RAEB, RAEB in T, and CMMoL, developed acute myeloid leukemia, but only 1 of 8 cats with low blast cell count MDS (RA) developed acute myeloid leukemia. Based on the Dusseldorf scoring system for the prognosis of human MDS, the survival times of the cats showing high scores (> or =3 points) were significantly shorter than those of the cats with low scores (<3 points). The FAB classification and Dusseldorf scoring system were considered to be useful for predicting the prognosis of feline MDS. Furthermore, 15 of the 16 cats with MDS in this study were infected with feline leukemia virus, indicating its possible etiologic role in the pathogenesis of feline MDS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11596735     DOI: 10.1892/0891-6640(2001)015<0471:haaooc>2.3.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  2 in total

1.  The kinetics of clonal dominance in myeloproliferative disorders.

Authors:  Sandra N Catlin; Peter Guttorp; Janis L Abkowitz
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

2.  A cat with myelodysplastic syndrome by administration of the methylation inhibitor Azacytidine.

Authors:  Masaharu Hisasue; Mina Tanaka; Sakurako Neo
Journal:  J Vet Med Sci       Date:  2021-12-06       Impact factor: 1.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.